COVID-19 Related Inhibitors
Catalog No. Product Name Information Reference
S4430 Hydroxychloroquine Sulfate Hydroxychloroquine Sulfate is an antimalarial agent used for the treatment of systemic lupus erythematosus, rheumatoid arthritis and other autoimmune, inflammatory and dermatologic conditions. Also acts as an inhibitor of autophagy and toll-like receptor (TLR) 7/9. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial
S2853 Carfilzomib (PR-171) Carfilzomib (PR-171) is an irreversible proteasome inhibitor with IC50 of <5 nM in ANBL-6 cells, displayed preferential in vitro inhibitory potency against the ChT-L activity in the β5 subunit, but little or no effect on the PGPH and T-L activities. Carfilzomib activates prosurvival autophagy and induces cell apoptosis. Fast Identification of Possible Drug Treatment of Coronavirus Disease -19 (COVID-19) Through Computational Drug Repurposing Study
S7975 Favipiravir (T-705) Favipiravir (T-705) is a potent and selective RNA-dependent RNA polymerase inhibitor, used to treat influenza virus infections. Discovering drugs to treat coronavirus disease 2019 (COVID-19)
S1835 Azithromycin Azithromycin is an antibiotic by inhibiting protein synthesis, used for the treatment of bacterial infections. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial
S1620 Darunavir Ethanolate Darunavir Ethanolate (DRV) is a nonpeptidic HIV protease inhibitor, used to treat HIV infection. Many drugs already approved by FDA may have promise against COVID-19
S4646 Ciclesonide Ciclesonide is a glucocorticoid used to treat obstructive airway diseases. Therapeutic potential of ciclesonide inhalation for COVID-19 pneumonia: Report of three cases
S3035 Daunorubicin HCl Daunorubicin HCl inhibits both DNA and RNA synthesis and inhibits DNA synthesis with Ki of 0.02 μM in a cell-free assay. Daunorubicin is a topoisomerase II inhibitor that induces apoptosis. Many drugs already approved by FDA may have promise against COVID-19
S4157 Chloroquine diphosphate Chloroquine diphosphate is a 4-aminoquinoline anti-malarial and anti-rheumatoid agent, also acting as an ATM activator. Chloroquine is also an inhibitor of toll-like receptors (TLRs). Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro
S2823 Tideglusib Tideglusib is an irreversible, non ATP-competitive GSK-3β inhibitor with IC50 of 60 nM in a cell-free assay; fails to inhibit kinases with a Cys homologous to Cys-199 located in the active site. Phase 2. Structure of M pro From COVID-19 Virus and Discovery of Its Inhibitors
S2874 Camostat Mesilate Camostat is a trypsin-like protease inhibitor, inhibits airway epithelial sodium channel (ENaC) function with IC50 of 50 nM, less potent to trpsin, prostasin and matriptase. The Impact of Camostat Mesilate on COVID-19 Infection (CamoCO-19)
S8932 Remdesivir (GS-5734) Remdesivir,a monophosphoramidate prodrug of an adenosine analog, is an investigational broad-spectrum antiviral agent with in vitro activity against multiple RNA viruses, including Ebola and CoV. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro
S5911 Bictegravir Bictegravir is a novel, potent, once-daily, unboosted inhibitor of HIV-1 integrase. Potential COVID-2019 3C-like Protease Inhibitors Designed Using Generative Deep Learning Approaches
S1759 Pitavastatin Calcium Pitavastatin Calcium, a novel member of the medication class of statins, is a calcium salt formulation of pitavastatin which is a highly effective HMG-CoA reductase inhibitor. Pitavastatin Calcium attenuates AGEs-induced mitophagy via inhibition of ROS generation. Pitavastatin Calcium induces autophagy and apoptosis. Potential COVID-2019 3C-like Protease Inhibitors Designed Using Generative Deep Learning Approaches
S1680 Disulfiram Disulfiram is a specific inhibitor of aldehyde-dehydrogenase (ALDH) with IC50 of 0.15 μM and 1.45 μM for hALDH1 and hALDH2, respectively. Disulfiram is used for the treatment of chronic alcoholism by producing an acute sensitivity to alcohol. Disulfiram induces apoptosis. Structure of M pro From COVID-19 Virus and Discovery of Its Inhibitors
S1386 Nafamostat Mesylate Nafamostat mesilate is a synthetic serine protease inhibitor, used as an anticoagulant during hemodialysis. Nafamostat mesylate blocks activation of SARS-CoV-2 and is investigated as a new treatment option for COVID-19. Nafamostat Mesilate attenuates inflammation and apoptosis. Nafamostat inhibits SARS-CoV-2 infection, preventing COVID-19 transmission
S1706 Lamivudine Lamivudine is a potent nucleoside analog reverse transcriptase inhibitor, used for treatment of chronic HBV and HIV/AIDS. It works by blocking the HIV reverse transcriptase and hepatitis B virus polymerase. COVID-19 Registered Trials – and analysis
S8279 Shikonin Shikonin, a potent and specific Pyruvate kinase M2 (PKM2) inhibitor, is a major component of zicao (purple gromwell, the dried root of Lithospermum erythrorhizon), a Chinese herbal medicine with various biological activities. It is also an inhibitor of TMEM16A chloride channel activity using cell-based fluorescent-quenching assay. Shikonin exerts an anti-inflammatory effect by inhibiting tumor necrosis factor-α (TNF-α) and prevents activation of nuclear factor-κB (NF-κB) pathway via proteasome inhibition.
S1380 Lopinavir Lopinavir is a potent HIV protease inhibitor with Ki of 1.3 pM in a cell-free assay. Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicin
S2485 Mitoxantrone 2HCl Mitoxantrone 2HCl is a dihydrochloride salt of Mitoxantrone. Mitoxantrone is an inhibitor of type II topoisomerase and protein kinase C (PKC) with IC50 of 8.5 μM for PKC. Mitoxantrone inhibits cell proliferative growth of MCF-7/wt cells with IC50 of 0.42 μM. Mitoxantrone also induces apoptosis. Many drugs already approved by FDA may have promise against COVID-19
S4282 Nelfinavir Mesylate Nelfinavir Mesylate is a potent HIV protease inhibitor with Ki of 2 nM. Potential COVID-2019 3C-like Protease Inhibitors Designed Using Generative Deep Learning Approaches
S1185 Ritonavir Ritonavir is a Cytochrome P450 3A and Protease Inhibitor; Also inhibits Cytochrome P450 2D6, P-Glycoprotein and induces Cytochrome P450 2C19, Cytochrome P450 1A2, Cytochrome P450 2C9, Cytochrome P450 2B6 and UDP Glucuronosyltransferases. Ritonavir induces apoptosis. Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicin
S1351 Ivermectin Ivermectin is a glutamate-gated chloride channel (GluCls) activator, used as a broad-spectrum antiparasitic drug. Parasite Drug Shows Early Promise Against COVID-19 in Vitro
S1401 Tenofovir Tenofovir blocks reverse transcriptase and hepatitis B virus infections. COVID-19 Registered Trials – and analysis
S5250 Darunavir Darunavir is a nonpeptidic HIV protease inhibitor, used to treat HIV infection. Many drugs already approved by FDA may have promise against COVID-19
S7579 Ledipasvir (GS5885) Ledipasvir (GS5885) is a HCV NS5A polymerase inhibitor, used for the treatment of hepatitis C virus infection. Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CL pro) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repur
S1538 Telaprevir (VX-950) Telaprevir (VX-950) is an HCV NS3-4A serine protease inhibitor with IC50 of 0.35 μM. α-Ketoamides as Broad-Spectrum Inhibitors of Coronavirus and Enterovirus Replication: Structure-Based Design, Synthesis, and Activity Assessment
S1183 Danoprevir (ITMN-191) Danoprevir(ITMN-191) is a peptidomimetic inhibitor of the NS3/4A protease of hepatitis C virus (HCV) with IC50 of 0.2-3.5 nM, inhibition effect for HCV genotypes 1A/1B/4/5/6 is ~10-fold higher than 2B/3A. Phase 2. First Clinical Study Using HCV Protease Inhibitor Danoprevir to Treat Naive and Experienced COVID-19 Patients
S2169 Rosuvastatin Calcium Rosuvastatin Calcium is a competitive inhibitor of HMG-CoA reductase with IC50 of 11 nM in a cell-free assay. Many drugs already approved by FDA may have promise against COVID-19
S1289 Carmofur Carmofur is a highly potent acid ceramidase inhibitor, used in the treatment of breast and colorectal cancer. Structure of M pro From COVID-19 Virus and Discovery of Its Inhibitors
S7947 PX-12 PX-12 is a potent thioredoxin-1 (Trx-1) inhibitor by irreversibly thioalkylation of Cys73 of Trx-1. Phase 2. Structure of M pro From COVID-19 Virus and Discovery of Its Inhibitors
S3079 Atovaquone Atovaquone is a medication used to treat or prevent for pneumocystis pneumonia, toxoplasmosis, malaria, and babesia. Many drugs already approved by FDA may have promise against COVID-19
S2926 TDZD-8 TDZD-8 is a non-ATP competitive GSK-3β inhibitor with IC50 of 2 μM; minimal inhibitory effect observed on CDK1, casein kinase II, PKA and PKC. Structure of M pro From COVID-19 Virus and Discovery of Its Inhibitors
S1691 Praziquantel Praziquantel is an anthelmintic effective against flatworms. Potential COVID-2019 3C-like Protease Inhibitors Designed Using Generative Deep Learning Approaches
S3733 Boceprevir Boceprevir is an oral, direct acting hepatitis C virus (HCV) protease inhibitor with Ki value of 14 nM for NS3. It is used in combination with other antiviral agents in the treatment of chronic hepatitis C, genotype 1. α-Ketoamides as Broad-Spectrum Inhibitors of Coronavirus and Enterovirus Replication: Structure-Based Design, Synthesis, and Activity Assessment
S3724 Velpatasvir Velpatasvir is a second-generation NS5A inhibitor that inhibits hepatitis C viral replication through acting on the crucial "membranous web" that facilitates RNA replication. Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CL pro) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repur
S2071 Prulifloxacin (NM441) Prulifloxacin, the prodrug of ulifloxacin, is a broad-spectrum oral fluoroquinolone antibacterial agent. Potential COVID-2019 3C-like Protease Inhibitors Designed Using Generative Deep Learning Approaches
S9567 Indinavir Sulfate Indinavir sulfate is a specific and potent inhibitor of HIV-1 protease and is widely used in the treatment of AIDS. Potential Therapeutic Agents for COVID-19 Based on the Analysis of Protease and RNA Polymerase Docking
S2079 Moexipril HCl Moexipril HCl is a potent orally active nonsulfhydryl angiotensin converting enzyme (ACE) inhibitor, used for the treatment of hypertension and congestive heart failure. Many drugs already approved by FDA may have promise against COVID-19
S3037 Bepotastine Besilate Bepotastine is a non-sedating, selective antagonist of histamine 1 (H1) receptor with pIC50 of 5.7. Many drugs already approved by FDA may have promise against COVID-19
S5940 Bepotastine Bepotastine is a non-sedating, selective antagonist of the histamine 1 (H1) receptor that is indicated in allergic rhinitis, urticaria, and pruritus associated with skin disease. Many drugs already approved by FDA may have promise against COVID-19
S6676 Ebselen Ebselen is a small-molecule capsid inhibitor of HIV-1 Replication with IC50 of 46.1 nM in TR-FRET assay. Structure of M pro From COVID-19 Virus and Discovery of Its Inhibitors
S8969 EIDD-2801 EIDD-2801 is an orally bioavailable prodrug of the ribonucleoside analog β-d-N4-hydroxycytidine (NHC; EIDD-1931) with broad-spectrum antiviral activity against SARS-CoV-2, MERS-CoV, SARS-CoV, and the causative agent of COVID-19. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice
COVID-19 Related Antibodies
Catalog No. Product Name Information Reference
A2012 Tocilizumab (anti-IL-6R) Tocilizumab (anti-IL-6R) is a humanized monoclonal antibody that binds to the interleukin-6 receptor, MW: 148 KD. Tocilizumab treatment in COVID‐19: A single center experience
A2011 Sarilumab (anti-IL-6Rα) Sarilumab (anti-IL-6Rα) is a fully human anti-IL-6Rα mAb that binds membrane-bound and soluble human IL-6Rα with high affinity, MW: 144.13 KD. After disappointing early numbers, Sanofi and Regeneron scale back Kevzara's COVID-19 test
COVID-19 Related Compound Libraries
Catalog No. Product Name Information
L7000 Antiviral Compound Library A unique collection of 347 antiviral compounds used for exploring novel antiviral drug.
L7200 Nucleoside Analogue Library A unique collection of 135 nucleoside analogues used for high throughput screening(HTS) and high content screening(HCS).